Stocks / NASDAQ / AgomAb Therapeutics NV

AgomAb Therapeutics NV

Industry: Health Care – Biotechnology: Biological Products (No Diagnostic Substances)

Stock Symbol: AGMB – NASDAQ

Animal Usage: Animal Testing

Our Opinion

AgomAb Therapeutics NV is on the Cruelty Free Investing list for exploiting animals because the company does animal testing to assess a product’s safety profile.

Supporting Evidence:

The company stated in the following report that they exploit animals for drug testing.

“Ontunisertib (AGMB-129) is designed to undergo rapid liver metabolism and has been shown to have very short half-life in vitro in human hepatocytes as well as in hepatocytes from several animal species.” (Page 121) Read the full document

Company Description

AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company’s product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn’s disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials. The company was incorporated in 2017 and is headquartered in Antwerp, Belgium.

Company Website: https://agomab.com

Contact: info@agomab.com